

# ELI LILLY AND COMPANY

ISIN: US5324571083 WKN: 532457108 Asset Class: Stock



## Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	25,727,000,000		18,034,500,000		18,452,400,000	
<b>Common stock capital</b>		593,600,000		594,100,000		596,300,000
<b>Fixed assets</b>	38,279,300,000		31,455,300,000		30,353,600,000	
<b>Equity capital of a company</b>		10,863,700,000		10,775,400,000		9,154,800,000
<b>Cash and cash equivalents</b>	2,818,600,000		2,067,000,000		3,818,500,000	
<b>Accrued liabilities</b>		1,438,800,000		1,305,100,000		1,954,100,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		27,293,200,000		17,138,200,000		15,052,700,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		25,849,400,000		21,576,200,000		24,598,500,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		6,089,800,000		5,446,300,000		5,564,300,000
<b>Total assets</b>	64,006,300,000	64,006,300,000	49,489,800,000	49,489,800,000	48,806,000,000	48,806,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	43,000	39,000	35,000
<b>Equity ratio</b>	17.12%	22.03%	19.12%
<b>Debt-equity ratio</b>	484.24%	353.99%	423.09%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	20.05%	8.25%	9.32%

# ELI LILLY AND COMPANY

ISIN: US5324571083 WKN: 532457108 Asset Class: Stock

## Income statement

	2023	2022	2021
Turnover	34,124,100,000	28,541,400,000	28,318,400,000
Net income	5,240,400,000	6,244,800,000	5,581,700,000
EBIT	6,363,556,230	6,556,587,840	5,995,656,330
Operating income before taxes	6,554,600,000	6,806,400,000	6,155,500,000
Cash Flow	4,240,100,000	7,084,400,000	7,260,700,000
Net interest income	-312,300,000	-268,800,000	-314,400,000
Research and development expenses	9,313,400,000	7,190,800,000	7,025,900,000
Income taxes	1,314,200,000	561,600,000	573,800,000
Result from investments in subsidiaries, associates and other	0	-	-
Revenues per employee	735,414	678,188	749,790

## Board of Directors

## Members of Management Board

Katherine Baicker	Member of Board of Directors
Marschall Runge	Member of Board of Directors
Mary Lynne Hedley	Member of Board of Directors
William Kaelin	Member of Board of Directors
Gabrielle Greene-Sulzberger	Member of Board of Directors
Jamere Jackson	Member of Board of Directors
Jon Fyrwald	Member of Board of Directors
Juan Luciano	Member of Board of Directors
Karen Walker	Member of Board of Directors
Kimberly Johnson	Member of Board of Directors
Ralph Alvarez	Member of Board of Directors
David Ricks	Chairman of Managing Board
Alonzo Weems	Member of Executive Committee
Anat Ashkenazi	Member of Executive Committee
Anat Hakim	Member of Executive Committee
Anne E. White	Member of Executive Committee
Daniel M. Skovronsky	Member of Executive Committee
Diogo Rau	Member of Executive Committee
Edgardo Hernandez	Member of Executive Committee
Eric Dozier	Member of Executive Committee
Ilya Yuffa	Member of Executive Committee
Jacob Van Naarden	Member of Executive Committee
Johna L. Norton	Member of Executive Committee
Patrik Jonsson	Member of Executive Committee